+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Proteomics: Technologies and Global Markets

  • PDF Icon

    Report

  • 384 Pages
  • December 2022
  • Region: Global
  • BCC Research
  • ID: 4618078

The study’s scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays, and LOACs. It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets - North America, Europe, Asia-Pacific, and Rest of the World (ROW) - are included.

The MS market is covered by instrument type, MS consumables, and product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth to 2027.

Technology status and forces driving the market are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs, and competitive trends.

Key industry acquisitions and strategic alliances are given for the five-year period from 2021 through 2027.

This report examines the main patent trends within the industry and profiles proteomics companies.

Report Includes

  • 149 data tables and 97 additional tables
  • An up-to-date overview of the global markets for proteomics and related technologies
  • Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the upcoming market potential for the global proteomics industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and market forecast for proteomics in value (USD millions) terms, and their corresponding market share analysis by platform technology, end-user application, and region
  • In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in proteomics, and COVID-19 impact on the market for proteomics
  • Insight into recent industry structure for proteomics technologies, competitive aspects of each product segments, major growth strategies, and company value share analysis based on their segmental revenues
  • Updated information on key mergers and acquisition deals, agreements, partnerships, collaborations and product launches within the global proteomics industry
  • Profile descriptions of the leading proteomics manufacturers, including Agilent, Danaher Corp., GlaxoSmithKline PLC, PerkinElmer Inc., Qiagen GmbH, and Sanofi.
Frequently Asked Questions about the Global Proteomics Market

What is the estimated value of the Global Proteomics Market?

The Global Proteomics Market was estimated to be valued at $27.1 Billion in 2022.

What is the growth rate of the Global Proteomics Market?

The growth rate of the Global Proteomics Market is 15.3%, with an estimated value of $55.1 Billion by 2027.

What is the forecasted size of the Global Proteomics Market?

The Global Proteomics Market is estimated to be worth $55.1 Billion by 2027.

Who are the key companies in the Global Proteomics Market?

Key companies in the Global Proteomics Market include Abcodia Ltd., Activx Biosciences Inc., Advanced Proteome Therapeutics Inc., Agilent Technologies Inc., Applied Proteomics, Arrayit Corp., Astute Medical Inc., Avacta Life Sciences Ltd., Ayoxxa Biosystems GmbH and Becton, Dickinson and Co..

Table of Contents

Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing the Study
1.3 What's New in this Update?
1.4 Scope of Report
1.5 Intended Audience
1.6 Methodology
1.7 Information Sources
1.8 Analyst's Credentials
1.9 Custom Research
1.10 Related Research Reports

Chapter 2 Summary and Highlights
Chapter 3 Overview
3.1 Proteomic Technologies
3.2 Scope of Report
3.3 Proteomics Market
3.4 Driving Forces for Proteomics Industry Growth
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities
3.4.4 Challenge
3.4.5 Proteomics Industry

Chapter 4 Covid 19 Impact on Proteomics Market
4.1 Overview
4.2 Covid-19 Crisis
4.3 Impact on Market
4.4 Current Outlook
4.4.1 Implications on Cancer Diagnosis
4.4.2 Key Reasons for Impact of Covid-19

Chapter 5 Proteomics Technologies
5.1 Introduction
5.2 Ms-Based Proteomics Technologies
5.2.1 Sample Preparation Assays
5.2.2 Tagging/Affinity Methods
5.2.3 Utility of Proteomics to Identify Biomarkers
5.2.4 Ms Instruments and Consumables
5.3 Biochip-Based Proteomics Technologies
5.3.1 Multiplex Proteomics Systems
5.3.2 Proteogenomics
5.3.3 Recent Advances in Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development
6.1 Target Discovery
6.2 Lead Identification
6.3 Lead Optimization
6.4 Preclinical Studies

Chapter 7 Proteomics Scientific Initiatives
Chapter 8 Clinical Proteomics Applications
8.1 Applications in Cancer
8.1.1 Overview
8.1.2 Bladder Cancer
8.1.3 Breast Cancer
8.1.4 Colorectal Cancer
8.1.5 Gastric Cancer
8.1.6 Kidney Cancer
8.1.7 Lung Cancer
8.1.8 Lymphomas
8.1.9 Ovarian Cancer
8.1.10 Pan-Cancer
8.1.11 Prostate Cancer
8.1.12 Thyroid Cancer
8.1.13 Other Cancers
8.2 Infectious Diseases
8.3 Diabetes
8.4 Neurological Disorders
8.4.1 Alzheimer's Disease
8.4.2 Schizophrenia
8.5 Immune Diseases
8.5.1 Hla Typing
8.5.2 Autoimmune Disease
8.6 Cardiovascular Disease
8.7 Preeclampsia

Chapter 9 Proteomics Industry
9.1 Industry Acquisitions
9.2 Industry Strategic Alliances
9.3 Mass Spectrometry Industry
9.4 Chromatography Industry
9.5 Proteomics-Based Drug Discovery and Development Industry
9.6 Proteomics Biochip Industries
9.6.1 Peptide Microarray Industry
9.6.2 High-Density Protein Array Industry
9.7 Antibody Microarray Industry
9.8 China's Biochip Industry
9.9 Lab-On-A-Chip Proteomics Industry
9.10 Chemical Proteomics Industry
9.11 Antibody Reagent Industry
9.12 Multiplex Protein Diagnostics Industry
9.13 Dried Blood Spotting Proteomics Industry
9.14 Single Cell Proteomics Industry

Chapter 10 Proteomics Markets
10.1 Driving Forces of Proteomics Industry Growth
10.2 Global Proteomics Markets
10.3 Market Summary
10.4 Research Market
10.5 Drug Discovery and Development Market
10.6 Proteomics Diagnostic Market
10.7 Mass Spectrometry-Based Proteomics Market
10.8 Biochip-Based Proteomics Market

Chapter 11 Proteomics Market by Geographic Segmentation
11.1 North America
11.1.1 United States
11.1.1 Canada
11.2 Europe
11.2.1 Impact of Brexit
11.2.2 United Kingdom
11.2.3 Germany
11.2.4 France
11.2.5 Italy
11.2.6 Spain
11.2.7 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Rest of Asia-Pacific
11.4 Rest of the World (Row)

Chapter 12 Proteomics Patents
12.1 U.S. Proteomics Patents
12.2 Protein Array Patents
12.2.1 Lab-On-A-Chip Patents
12.2.2 Mass Spectrometry Patents

Chapter 13 Competitive Landscape
13.1 Genomics and Proteomic Tools/Technologies
13.1.1 Sequencing Technologies
13.1.2 Pcr Technology
13.1.3 Nucleic Acid Purification and Separation
13.1.4 Nucleic Acid Separation Technologies

Chapter 14 Company Profiles
  • Abcodia Ltd.
  • Activx Biosciences Inc.
  • Advanced Proteome Therapeutics Inc.
  • Agilent Technologies Inc.
  • Applied Proteomics
  • Arrayit Corp.
  • Astute Medical Inc.
  • Avacta Life Sciences Ltd.
  • Ayoxxa Biosystems GmbH
  • Becton, Dickinson and Co.
  • Biocartis Nv
  • Biodesix Inc.
  • Biognosys AG
  • Biomerieux Sa
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Inc.
  • Bruker Corp.
  • Cambridge Protein Arrays Ltd.
  • Charles River Laboratories International Inc.
  • Crystalgenomics Inc.
  • Danaher Corp.
  • Epicypher Inc.
  • Evotec AG
  • General Electric Co.
  • GlaxoSmithKline plc
  • Gl Sciences Inc.
  • Illumina Inc.
  • Immunovia Ab
  • Imtakt Corp.
  • Integrated Diagnostics Holding
  • Indi Molecular
  • Labcyte Inc.
  • Liminal Biosciences Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Mrm Proteomics Inc.
  • Mycartis
  • Myriad Genetics Inc.
  • Newomics Inc.
  • Nirmidas Biotech Inc.
  • Olink Bioscience
  • Opko Health Inc.
  • Perkinelmer Inc.
  • Personalized Cancer Therapy Inc.
  • Pfizer Inc.
  • Phenomenex Inc.
  • Pressure Biosciences Inc.
  • Protagen AG
  • Protea Biosciences Inc.
  • Proteocyte Diagnostics Inc.
  • Proteogenix
  • Proteome Sciences plc
  • Proteomics International Pty Ltd.
  • Pyc Therapeutics. (Formerly Phylogica Ltd.)
  • Qiagen N.V.
  • Quansys Biosciences
  • Quanterix Inc.
  • Quest Diagnostics Inc.
  • Repligen Corp.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Samdi Tech Inc.
  • Sanofi
  • Sera Prognostics
  • Shimadzu Corp.
  • Shiseido Company Ltd.
  • Showa Denko Kk
  • Singulex Inc.
  • Siscapa Assay Technologies Inc.
  • Somalogic Inc.
  • Spoton Clinical Diagnostics Ltd.
  • Sqi Diagnostics
  • Standard Biotools Inc. (Formerly Fluidigm)
  • Synageva Biopharma (Acquired by Alexion Pharmaceuticals Inc.)
  • T2 Biosystems
  • Thermo Fisher Scientific Inc.
  • Thorne Diagnostics Inc.
  • Tosoh Corp.
  • Trajan Scientific and Medical
  • Universal Biosensors Ltd.
  • Vg Life Sciences Inc.
  • Waters Corp.
  • Xencor Inc.
  • Ymc Co. Ltd.
List of Tables
Summary Table A: Global Proteomics Market, by End-User Industry, Through 2027
Summary Table B: Global Proteomics Market, by Platform, Through 2027
Table 1: Global Array Versus Lab-on-a-Chip (LOC) Biochips
Table 2: Scope of Report
Table 3: Global Proteomics Market, by Platform, Through 2027
Table 4: Global Biochips Market, by Type, Through 2027
Table 5: Driving Forces in the Growth of the Proteomics Industry
Table 6: Biochip Industry Comparisons
Table 7: Mass Spectrometry Generalized Workflow Schematic
Table 8: Mass Spectrometer Platforms
Table 9: Biochip-Based Proteomics Technologies
Table 10: Planar-Based Versus Bead-Based Arrays
Table 11: Advantages of Multiplexing for Diagnostics
Table 12: Technical Advances in Proteomics
Table 13: Proteomic Applications in Drug Discovery and Development
Table 14: Large-Scale Proteomics Initiatives
Table 15: Some Cancer Markers Used in Diagnosis and Treatment
Table 16: Strategies for Overcoming High-Abundance Proteins in Clinical Samples
Table 17: Status of Next-Generation Diagnostic Tests for Bladder Cancer
Table 18: Number of Annual Breast Cancer Treatment Decisions in the U.S, by Cancer Classification
Table 19: Breast Cancer MDx Technology Platforms
Table 20: Status of Next-Generation Tests for Breast Cancer
Table 21: Status of Next-Generation Diagnostic Tests for Gastric/Stomach Cancer
Table 22: Status of Next-Generation Diagnostic Tests for Kidney Cancer
Table 23: Status of Next-Generation Diagnostic Tests for Lung Cancer
Table 24: Status of Next-Generation Diagnostic Tests for Lymphomas
Table 25: Early Screening Tests for Ovarian Cancer
Table 26: Status of Next-Generation Diagnostics Tests for Ovarian Cancer
Table 27: Status of Next-Generation Diagnostics Tests for Pan-Cancer
Table 28: Status of Next-Generation Diagnostics Tests for Prostate Cancer
Table 29: Status of Next-Generation Diagnostics Tests for Thyroid Cancer
Table 30: Alzheimer's Disease Diagnostic Approaches
Table 31: Multiplex Autoimmune Testing Market
Table 32: Preeclampsia Diagnostic Tests
Table 33: Proteomics Industry Acquisitions, 2017-2022
Table 34: Strategic Alliances in the Proteomics Industry
Table 35: Mass Spectrometry Industry: Porter’s Five Forces Analysis
Table 36: First-Tier Mass Spectrometry Companies
Table 37: Second-Tier Mass Spectrometry Companies
Table 38: Leading Manufacturers of High-Performance Liquid Chromatography Columns
Table 39: Leading Manufacturers of High-Performance Liquid Chromatography Columns in Japan
Table 40: Proteomics-Based Drug Discovery Industry
Table 41: Key Peptide Microarray Companies
Table 42: Leading High-Density Protein Array Companies
Table 43: Key Antibody Microarray Companies
Table 44: Leading Companies in China's Biochip Industry
Table 45: Lab-on-a-Chip Competitor Landscape
Table 46: Antibody Reagent Market Share, by Company, 2021
Table 47: Multiplex Protein In Vitro Diagnostics Companies
Table 48: Dried Blood Spot Proteomics Industry
Table 49: Single Cell Proteomics Industry
Table 50: Factors Driving the Growth of the Proteomics Industry
Table 51: Global Proteomic Market, by End-User Industry, Through 2027
Table 52: Global Proteomics Research Market, by Platform, Through 2027
Table 53: Global Proteomics Research Market, by Biochip Platform, Through 2027
Table 54: Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 55: Global Proteomics Biochip Drug Discovery and Development Market, by Biochip Platform, Through 2027
Table 56: Global Proteomics Diagnostic Market, by Platform, Through 2027
Table 57: Global Proteomics Diagnostic Market, by Biochip Type, Through 2027
Table 58: Global Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 59: Status of Proteomics-Based Diagnostics for Diabetes, Neurological, Autoimmune, Infectious Disease, HLA Typing, and Cardiovascular Disease Applications
Table 60: Sepsis Diagnostics Industry
Table 61: Global Proteomics Cancer Diagnostic Market, by Indication, Through 2027
Table 62: Global Mass Spectrometry Market, by Product Type, Through 2027
Table 63: Global Mass Spectrometry Market, by End-User Industry, Through 2027
Table 64: MRM-MS versus MALDI MS in Clinical Applications
Table 65: Status of MS Clinical Test Platforms
Table 66: Phosphoproteomics Platforms for Cancer Applications
Table 67: Global Proteomics Biochip Market, by Type, Through 2027
Table 68: Global Proteomics Arrays Market, by Type, Through 2027
Table 69: Global Proteomics Market, by End-User Industry, Through 2027
Table 70: Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 71: Global Proteomics Lab-on-a-Chip Market, by End-User Industry, Through 2027
Table 72: Global Proteomics Market, by Region, Through 2027
Table 73: Global Proteomic Diagnostic Market, by Region, Through 2027
Table 74: North American Proteomics Market by Country, Through 2027
Table 75: North American Proteomics Market, by Platform, Through 2027
Table 76: North American Proteomics Market, by Biochips Platform, Through 2027
Table 77: North American Proteomics Market, by End User, Through 2027
Table 78: North American Drug Discovery and Development Market, by Platform, Through 2027
Table 79: North American Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 80: North American Proteomics Research Market, by Platform, Through 2027
Table 81: U.S. Proteomics Market, by Platform, Through 2027
Table 82: U.S. Proteomics Market, by Biochips Platform, Through 2027
Table 83: U.S. Proteomics Market, by End User, Through 2027
Table 84: U.S. Drug Discovery and Development Market, by Platform, Through 2027
Table 85: U.S. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 86: U.S. Proteomics Research Market, by Platform, Through 2027
Table 87: Canadian Proteomics Market, by Platform, Through 2027
Table 88: Canadian Proteomics Market, by Biochips Platform, Through 2027
Table 89: Canadian Proteomics Market, by End User, Through 2027
Table 90: Canadian Drug Discovery and Development Market, by Platform, Through 2027
Table 91: Canadian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 92: Canadian Proteomics Research Market, by Platform, Through 2027
Table 93: European Proteomics Market, by Country, Through 2027
Table 94: European Proteomics Market, by Platform, Through 2027
Table 95: European Proteomics Market, by Biochips Platform, Through 2027
Table 96: European Proteomics Market, by End User, Through 2027
Table 97: European Drug Discovery and Development Market, by Platform, Through 2027
Table 98: European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 99: European Proteomics Research Market, by Platform, Through 2027
Table 100: U.K. Proteomics Market, by Platform, Through 2027
Table 101: U.K. Proteomics Market, by Biochips Platform, Through 2027
Table 102: U.K. Proteomics Market, by End User, Through 2027
Table 103: U.K. Drug Discovery and Development Market, by Platform, Through 2027
Table 104: U.K. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 105: U.K. Proteomics Research Market, by Platform, Through 2027
Table 106: German Proteomics Market, by Platform, Through 2027
Table 107: German Proteomics Market, by Biochips Platform, Through 2027
Table 108: German Proteomics Market, by End User, Through 2027
Table 109: German Drug Discovery and Development Market, by Platform, Through 2027
Table 110: German Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 111: German Proteomics Research Market, by Platform, Through 2027
Table 112: French Proteomics Market, by Platform, Through 2027
Table 113: French Proteomics Market, by Biochips Platform, Through 2027
Table 114: French Proteomics Market, by End User, Through 2027
Table 115: French Drug Discovery and Development Market, by Platform, Through 2027
Table 116: French Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 117: French Proteomics Research Market, by Platform, Through 2027
Table 118: Italian Proteomics Market, by Platform, Through 2027
Table 119: Italian Proteomics Market, by Biochips Platform, Through 2027
Table 120: Italian Proteomics Market, by End User, Through 2027
Table 121: Italian Drug Discovery and Development Market, by Platform, Through 2027
Table 122: Italian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 123: Italian Proteomics Research Market, by Platform, Through 2027
Table 124: Spanish Proteomics Market, by Platform, Through 2027
Table 125: Spanish Proteomics Market, by Biochips Platform, Through 2027
Table 126: Spanish Proteomics Market, by End User, Through 2027
Table 127: Spanish Drug Discovery and Development Market, by Platform, Through 2027
Table 128: Spanish Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 129: Spanish Proteomics Research Market, by Platform, Through 2027
Table 130: Rest of European Proteomics Market, by Platform, Through 2027
Table 131: Rest of European Proteomics Market, by Biochips Platform, Through 2027
Table 132: Rest of European Proteomics Market, by End User, Through 2027
Table 133: Rest of European Drug Discovery and Development Market, by Platform, Through 2027
Table 134: Rest of European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 135: Rest of European Proteomics Research Market, by Platform, Through 2027
Table 136: Asia-Pacific Proteomics Market, by Country, Through 2027
Table 137: Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 138: Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 139: Asia-Pacific Proteomics Market, by End User, Through 2027
Table 140: Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 141: Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 142: Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 143: Chinese Proteomics Market, by Platform, Through 2027
Table 144: Chinese Proteomics Market, by Biochips Platform, Through 2027
Table 145: Chinese Proteomics Market, by End User, Through 2027
Table 146: Chinese Drug Discovery and Development Market, by Platform, Through 2027
Table 147: Chinese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 148: Chinese Proteomics Research Market, by Platform, Through 2027
Table 149: Japanese Proteomics Market, by Platform, Through 2027
Table 150: Japanese Proteomics Market, by Biochips Platform, Through 2027
Table 151: Japanese Proteomics Market, by End User, Through 2027
Table 152: Japanese Drug Discovery and Development Market, by Platform, Through 2027
Table 153: Japanese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 154: Japanese Proteomics Research Market, by Platform, Through 2027
Table 155: Indian Proteomics Market, by Platform, Through 2027
Table 156: Indian Proteomics Market, by Biochips Platform, Through 2027
Table 157: Indian Proteomics Market, by End User, Through 2027
Table 158: Indian Drug Discovery and Development Market, by Platform, Through 2027
Table 159: Indian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 160: Indian Proteomics Research Market, by Platform, Through 2027
Table 161: South Korean Proteomics Market, by Platform, Through 2027
Table 162: South Korean Proteomics Market, by Biochips Platform, Through 2027
Table 163: South Korean Proteomics Market, by End User, Through 2027
Table 164: South Korean Drug Discovery and Development Market, by Platform, Through 2027
Table 165: South Korean Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 166: South Korean Proteomics Research Market, by Platform, Through 2027
Table 167: Australian Proteomics Market, by Platform, Through 2027
Table 168: Australian Proteomics Market, by Biochips Platform, Through 2027
Table 169: Australian Proteomics Market, by End User, Through 2027
Table 170: Australian Drug Discovery and Development Market, by Platform, Through 2027
Table 171: Australian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 172: Australian Proteomics Research Market, by Platform, Through 2027
Table 173: Rest of Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 174: Rest of Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 175: Rest of Asia-Pacific Proteomics Market, by End User, Through 2027
Table 176: Rest of Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 177: Rest of Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 178: Rest of Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 179: Rest of the World Proteomics Market, by Platform, Through 2027
Table 180: Rest of the World Proteomics Market, by Biochips Platform, Through 2027
Table 181: Rest of the World Proteomics Market, by End User, Through 2027
Table 182: Rest of the World Drug Discovery and Development Market, by Platform, Through 2027
Table 183: Rest of the World Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 184: Rest of the World Proteomics Research Market, by Platform, Through 2027
Table 185: U.S. Proteomics Patents, 2017-2022
Table 186: Europe: Proteomics Patents, 2017-2022
Table 187: Japan: Proteomics Patents, 2017-2022
Table 188: Array-related Proteomics Patents, by Region, 2017-2022
Table 189: LOC-Related Proteomics Patents, by Region, 2017-2022
Table 190: Mass Spectrometry-Related Proteomics Patents, by Region, 2017-2022
Table 191: Major Mergers, Acquisitions, Collaborations, Partnership, Spin-Offs and Agreements
Table 192: FDA Clearances, Patents and Approvals, 2017-2022
Table 193: New Product Launches, 2017-2022
Table 194: Key Products of Sequencing and Next-Generation Sequencing Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 195: Top Manufacturers of PCR Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 196: Key Products of PCR Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 197: Top Manufacturers of Nucleic Acid Purification and Extraction Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 198: Key Products of Nucleic Acid Purification and Extraction Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 199: Top Manufacturers of Nucleic Acid Separation Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 200: Nucleic Acid Separation Technologies: Key Manufacturers’ Product Portfolio
Table 201: Agilent: Laboratory Automation Systems and Processes Portfolio
Table 202: Agilent Technologies Inc.: Developments
Table 203: BD: Laboratory Automation Systems and Processes Portfolio
Table 204: BioMerieux: FDA Bacteriology Products Approved in 2020
Table 205: BioMerieux: Key Developments, 2021
Table 206: Bio-Rad: Key Developments, 2021
Table 207: Danaher Corp.: Key Developments
Table 208: GE Healthcare: Product Portfolio
Table 209: General Electric: Financials, 2019
Table 210: GE Healthcare: Product Portfolio
Table 211: GE Healthcare: Recent Developments
Table 212: GlaxoSmithKline PLC: Product Segment
Table 213: GlaxoSmithKline PLC: Key Financials, 2021
Table 214: GlaxoSmithKline PLC: Vaccines Offered
Table 215: GlaxoSmithKline PLC: Flu Vaccines Sales
Table 216: GlaxoSmithKline PLC: Recent Developments
Table 217: Illumina Inc.: Revenues and R&D Expenditures
Table 218: Illumina Inc.: Key Developments
Table 219: PerkinElmer Inc.: Revenues and R&D Expenditures
Table 220: PerkinElmer Inc.: Laboratory Automation Systems and Processes Portfolio
Table 221: PerkinElmer Inc.: Selected Recent Developments
Table 222: Pressure BioSciences Inc.: Revenues and R&D Expenditures
Table 223: Pressure BioSciences Inc.: Key Developments
Table 224: Qiagen GmbH: Laboratory Automation Systems and Processes Portfolio
Table 225: Qiagen GmbH: Developments
Table 226: Roche: Business Segment
Table 227: Roche: Financials, 2021
Table 228: Roche: Financial Performance, 2018-2020
Table 229: Roche: Product Portfolio
Table 230: Roche: Diagnostics Patient Monitoring Product Portfolio
Table 231: Roche: Oncology Pharmaceutical Product Portfolio
Table 232: Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 233: Roche: Recent Developments
Table 234: Sanofi: Business Segment
Table 235: Sanofi: Financial Performance, 2021
Table 236: Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio
Table 237: Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 238: Somalogic: Proteomics Methods
Table 239: Thermo Fisher Scientific Inc.: Product Portfolio
Table 240: Thermo Fisher Scientific Inc.: Developments
Table 241: Universal Biosensors Diagnostic Pipeline
Table 242: Waters Corp.: Revenues and R&D Expenditures
Table 243: Waters Corp.: Laboratory Automation Systems and Processes Portfolio
Table 244: Waters Corp.: Key Developments

List of Figures
Summary Figure A: Global Proteomics Market, by End-User Industry, 2019-2027
Summary Figure B: Global Proteomics Market, by Platform, 2022-2027
Figure 1: Proteomics Biochip and Array Formats
Figure 2: Chromatography Proteomics Workflow
Figure 3: Agilent: Annual Revenue, Life Sciences and Applied Markets Segment, 2019-2021
Figure 4: Agilent: Revenue Share, by Region, Life Sciences and Applied Markets Segment, 2021
Figure 5: Danaher Corp.: Revenue Share, by Segment, 2020
Figure 6: Danaher: Life Sciences Segment, Annual Revenue, 2019-2021
Figure 7: Danaher: Life Sciences Segment Revenue Share, by Region, 2021
Figure 8: General Electric Co.: Revenue Share, by Complementary Segment, 2020
Figure 9: General Electric Co.: Revenue Share, by Region/Country, 2020
Figure 10: GE Healthcare: Revenue Share, by Region, 2019
Figure 11: GE Healthcare: Revenue Share, by Segment, 2019
Figure 12: GlaxoSmithKline PLC: Net Revenue, 2016-2021
Figure 13: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
Figure 14: GlaxoSmithKline PLC: Revenue Share, by Region, 2021
Figure 15: Merck KGaA: Revenue Share, by Complementary Segment, 2020
Figure 16: Merck KGaA: Annual Revenue, 2017-2020
Figure 17: Merck KGaA: Revenue Share, by Region, 2020
Figure 18: Merck KGaA: Revenue Share, by Investment, 2020
Figure 19: Merck KGaA: Revenue Share, by Region, 2020
Figure 20: PerkinElmer Inc.: Annual Revenue, 2019-2021
Figure 21: PerkinElmer Inc.: Revenue Share, by Region, 2021
Figure 22: Qiagen: Annual Revenue, 2019-2021
Figure 23: Qiagen: Revenue Share, by Product Groups, 2021
Figure 24: Qiagen: Revenue Share, by Region, 2021
Figure 25: Roche: Revenue Share, by Segment, 2021
Figure 26: Roche: Total Sales Share, by Product Segment, 2020
Figure 27: Roche: Annual Revenue, 2019-2021
Figure 28: Roche Core Laboratory Diagnostics Segment: Annual Revenue, 2019-2021
Figure 29: Roche: Oncology Annual Revenue, 2018-2020
Figure 30: Sanofi: Net Sales Share, by Business Segment, 2021
Figure 31: Sanofi: Net Sales Share, by Region, 2021
Figure 32: Sanofi Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 33: Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2020
Figure 34: Thermo Fisher Scientific: Annual Revenue, 2019-2021
Figure 35: Thermo Fisher Scientific: Revenue Share, by Region, 2021
Figure 36: Waters Corp.: Annual Revenue, 2019-2021
Figure 37: Waters Corp.: Revenue Share, by Region, 2021

Executive Summary

In May 2014, two independent research groups, one in the U.S. and India, and the other in Germany, published the first drafts of the human proteome, which was based on mass spectrometry data. These maps were the most comprehensive to date and signaled the rapid progress in our understanding of the role of genes and their products, proteins.

Approximately 5 million scientists are working on biological sample preparation in more than 80,000 laboratories globally. Major factors impacting the market are increased spending on research and development in developing economies. China is emerging as a global leader in sequencing and an increasing number of genomics projects run by Chinese agencies and other companies throughout the globe are creating genome libraries. There is also increased interest in personal genetics. Many companies, including Google, are investing in genomics start-ups. Along with this growth in genomics and proteomics, is a growing concern regarding data security and privacy. Personal genomics kits
currently sold directly to consumers have become a growing concern for the U.S. Food and Drug Administration (FDA).

The draft human proteome signaled the coming of age of proteomics, a field that is rapidly transitioning from research and development application to more applied fields including diagnostics. The two key proteomics technologies—mass spectrometry and biochips—are benefiting from an explosion of new proteomics content from the large-scale genomic and proteomic initiatives. For instance, according to the Journal of Proteome Research, ACS Publications, the Human Proteome Organization (HUPO) has introduced the Proteomics Standards Initiative (PSI) that is exploring software tools and open community standards in proteomics over the last 15 years (from 2002). Further, HUPO is also credited with completing protein parts list for the draft human proteome. In addition, HUPO is also exploring the application of proteomics for integration with genomics and transcriptomics across life sciences and biomedical research. This proteomics content is driving the discovery of new biomarkers that are important in disease diagnostic processes such as cancer diagnostics, myocardial infarction, congestive heart failure, and others.

Novel technologies are also driving proteomics applications. For example, increasing miniaturization and integration is occurring in biochip devices, and improvements in mass spectrometry workflow and instruments. These innovations are driving proteomics applications in important markets like drug discovery and development and diagnostics. For instance, in 2017, as per the European Association of Urology, the Israeli Institute of Technology developed a silicon biosensor chip that can identify the best antibiotics in just a few hours instead of days and can help in treating a bacterial infection. Furthermore, in 2017, the Georgia Institute of Technology presented that replacing conventional power supplies with Triboelectric Nano-generators (TENG) for charging molecules can boost up sensitivity of mass spectrometers and can also help in identification of small volumes.

Companies Mentioned

  • Abcodia Ltd.
  • Activx Biosciences Inc.
  • Advanced Proteome Therapeutics Inc.
  • Agilent Technologies Inc.
  • Applied Proteomics
  • Arrayit Corp.
  • Astute Medical Inc.
  • Avacta Life Sciences Ltd.
  • Ayoxxa Biosystems GmbH
  • Becton, Dickinson and Co.
  • Biocartis Nv
  • Biodesix Inc.
  • Biognosys AG
  • Biomerieux Sa
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Inc.
  • Bruker Corp.
  • Cambridge Protein Arrays Ltd.
  • Charles River Laboratories International Inc.
  • Crystalgenomics Inc.
  • Danaher Corp.
  • Epicypher Inc.
  • Evotec AG
  • General Electric Co.
  • GlaxoSmithKline plc
  • Gl Sciences Inc.
  • Illumina Inc.
  • Immunovia Ab
  • Imtakt Corp.
  • Integrated Diagnostics Holding
  • Indi Molecular
  • Labcyte Inc.
  • Liminal Biosciences Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Mrm Proteomics Inc.
  • Mycartis
  • Myriad Genetics Inc.
  • Newomics Inc.
  • Nirmidas Biotech Inc.
  • Olink Bioscience
  • Opko Health Inc.
  • Perkinelmer Inc.
  • Personalized Cancer Therapy Inc.
  • Pfizer Inc.
  • Phenomenex Inc.
  • Pressure Biosciences Inc.
  • Protagen AG
  • Protea Biosciences Inc.
  • Proteocyte Diagnostics Inc.
  • Proteogenix
  • Proteome Sciences plc
  • Proteomics International Pty Ltd.
  • Pyc Therapeutics. (Formerly Phylogica Ltd.)
  • Qiagen N.V.
  • Quansys Biosciences
  • Quanterix Inc.
  • Quest Diagnostics Inc.
  • Repligen Corp.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Samdi Tech Inc.
  • Sanofi
  • Sera Prognostics
  • Shimadzu Corp.
  • Shiseido Company Ltd.
  • Showa Denko Kk
  • Singulex Inc.
  • Siscapa Assay Technologies Inc.
  • Somalogic Inc.
  • Spoton Clinical Diagnostics Ltd.
  • Sqi Diagnostics
  • Standard Biotools Inc. (Formerly Fluidigm)
  • Synageva Biopharma (Acquired by Alexion Pharmaceuticals Inc.)
  • T2 Biosystems
  • Thermo Fisher Scientific Inc.
  • Thorne Diagnostics Inc.
  • Tosoh Corp.
  • Trajan Scientific and Medical
  • Universal Biosensors Ltd.
  • Vg Life Sciences Inc.
  • Waters Corp.
  • Xencor Inc.
  • Ymc Co. Ltd.